United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - carbinoxamine maleate (unii: 02o55696wh) (carbinoxamine - unii:982a7m02h5) - carbinoxamine maleate 4 mg - carbinoxamine maleate is effective for the symptomatic treatment of: seasonal and perennial allergic rhinitis. vasomotor rhinitis. allergic conjunctivitis due to inhalant allergens and foods. mild, uncomplicated allergic skin manifestations of urticaria and angio-edema. dermatographism. as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. amelioration of the severity of allergic reactions to blood or plasma. carbinoxamine maleate is contraindicated in children younger than 2 years of age. carbinoxamine maleate is contraindicated in nursing mothers. carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (see drug interactions section).

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - urea 400 mg in 1 g - for debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 90 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70), sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfur 40 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 g in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.